Role of vasopressin signaling in the pathogenesis of diabetic nephropathy-Reference-Cited by-同舟云学术

Role of vasopressin signaling in the pathogenesis of diabetic nephropathy

Published:2021-09-15 Issue:6 Volume: Page:9-20
ISSN:
Container-title:Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)
language:ru
Short-container-title:

Author:

Margaryan Arus Garikovna¹^ORCID,Lebedeva Svetlana Anatolievna²^ORCID,Lisitsyna Dariya Mikhailovna³^ORCID,Sirotkina Polina Igorevna⁴^ORCID,Yakubova Lyudmila Aleksandrovna⁴^ORCID,Tarasov Vadim Vladimirovich¹^ORCID

Affiliation:

1. Department of Pharmacology, A. P. Nelyubin Institute of Pharmacy, FSAEI HE I. M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

2. Department of Pharmacology, A. P. Nelyubin Institute of Pharmacy, FSAEI HE I. M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia

3. enter for Preclinical Research, Institute for Translational Medicine and Biotechnology, Biomedical Science and Technology Park, Sechenov University

4. Faculty «International School «Medicine of the Future», field of training «Medical Biochemistry», FSAEI HE I. M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Abstract

The diabetic kidney disease (also known as diabetic nephropathy) is a major complication of diabetes mellitus and also the most common cause of chronic kidney disease. Elevated plasma levels of vasopressin are consistently observed in patients with either type 1 and type 2 diabetes mellitus and in animal models of diabetes mellitus. A role of enhanced vasopressin signaling in progression of the diabetic nephropathy to chronic kidney disease has been suggested in several epidemiological studies but the underlying pathogenetic mechanisms remain largely unclear and are the subject of current scientific research.

Publisher

PANORAMA Publishing House

Reference26 articles.

1. Lise Bankir, Nadine Bouby, Eberhard Ritz. Vasopressin: a novel target for the prevention and retardation of kidney disease? // Nat. Rev. Nephrol. 9, 223–239 (2013);Epub 2013 Feb 26. PMID: 23438973. DOI: 10.1038/nrneph.2013.22.

2. Pascale Bardoux, Hélène Martin, Mina Ahloulay, François Schmitt, Nadine Bouby,Marie-Marcelle Trinh-Trang-Tan, et Lise Bankir. Vasopressin contributes to hyperfiltration,albuminu ria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats // Edited by Gerhard Giebisch, Yale University School of Medicine, New Haven, CT, and approved June 30, 1999 (received for review February 26, 1999). Proceedings of the National Academy of Sciences, 96 (18),10397–10402. DOI: 10.1073/pnas.96.18.10397.

3. El Boustany R. Vasopressin and Diabetic Kidney Disease // Annals of Nutrition and Metabolism. 2018 June; 72 (suppl 2): 17–20. DOI: 10.1159/000488124.

4. Ray El Boustany, Christopher Taveau, Catherine Chollet, Gilberto Velho, Lise Bankir,François Alhenc-Gelas, Ronan Roussel, Nadine Bouby. Antagonism of vasopressin V2 receptor improves albuminu ria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes // Journal of Diabetes and its Complications. 2017 Jun;31 (6): 929–932. DOI: 10.1016/j.jdiacomp.2017.04.005.

5. David H. Ellison, Tomas Berl. The Syndrome of Inappropriate Antidiuresis //New England Jou rnal of Medicine. May 2007; 356: 2064–2072. DOI: 10.1056/NEJMcp066837.